Use Twitter and Facebook to Market and Grow Your Business
Uploaded by: steinarknutsenDescription:
www.steinarknutsen.com Twitter and Facebook can help grow your business online. These are the two most popular social media marketing networks and if use appropriately you can effectively find and engage customers in conversation. Maybe you want to provide customer support or communicate new offers in a timely basis. The key is these platforms offer a place to listen to your market and engage in dialogue to better understand the needs of your new and existing customers. In this video I highlight the key considerations such as - Find prospects in your niche market - Connect with existing customers - Bring personality to your business - Share time-sensitive news & offers - Drive traffic back to your website - Deliver responsive customer service - Monitor competitive activity
Tags: twitter-and-facebook facebook-for-business marketing-with-facebook find-customers-on-facebook twitter-for-business marketing-with-twitter find-customers-on-twitter twitter-market-research facebook-niche-marketing social-media-advertising Dr. Charles Dinarello Co-Authors Article on AAT Research for OmniBio
Uploaded by: OmniBioPDescription:
Dr. Charles Dinarello, Chief Scientific Officer of OmniBio, is a co-author of an article that is now available in the journal Blood, which is the premier journal of the American Society of Hematology. The paper describes the use of Alpha 1 antitrypsin (AAT) to treat mice with a lethal form of rejection of bone marrow transplantation. Mice survive the crisis with AAT treatment. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com
Tags: graft host disease bone marrow transplant clinical trials alpha type 1 mellitus research cure alpha-1 antitrypsin aat jdrf juvenile children's diabetes foundation pharmaceutical industry stock investment opportunity angel investor equity development public company business finance funding portfolio venture capital startup small cap market financing healthcare health care medical westmountain West Mountain Asset Management Omni Bio James Crapo Charles Dinarello University of Colorado Type 1 Diabetes Research Update - Dr. Charles Dinarello on AAT Research at OmniBio Pharmaceutical
Uploaded by: OmniBioPDescription:
Chief Scientific Officer (CSO) for OmniBio Dr. Charles Dinarello discusses Alpha-1 Antitrypsin (AAT) research and it's potential as a therapy for Type 1 diabetes. He is also a Professor of Medicine and Immunology at the University of Colorado Denver who has published over 700 original research articles on cytokines, particularly interleukin‐1 (IL‐1) and tumor necrosis factor, and is considered a "founding father" of cytokine biology. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com
Tags: graft host disease bone marrow transplant clinical trials alpha type 1 mellitus research cure alpha-1 antitrypsin aat jdrf juvenile children's diabetes foundation pharmaceutical industry stock investment opportunity angel investor equity development public company business finance funding portfolio venture capital startup small cap market financing healthcare health care medical westmountain West Mountain Asset Management Omni Bio James Crapo Charles Dinarello University of Colorado Social Media & Online Marketing Seminar Overview - CCAR
Uploaded by: marketing4mainstDescription:
Register for this CCAR Seminar here: tinyurl.com The Contra Costa Association of Realtors sponsors workshops and seminars that enable Realtors and business owners to be successful with social media and online marketing. fb.com These classes always include a tremendous amount of information on exactly what you should do, why it works, and how to get started. Each class offers a collection of tips, strategies and tools available to you in the world of social media and internet marketing The first seminar in this series is "How to Engage Your Market, Connect With Customers and Grow Your Business" Bring your notepad, curiosity and questions and learn some of the most effective social media and online marketing strategies, resources and best practices for attracting more business and sales The first seminar in this series of seven classes is FREE...In this introductory seminar we cover these topics... Blogs and websites LinkedIn YouTube and video marketing Mobile media and text message marketing Google Twitter Facebook Zillow Active Rain Craigslist And how to integrate traditional print media marketing The other upcoming seminars include... "How to Build Your LinkedIn Foundation to Grow Your Business" In this seminar you will discover... How to Optimize Your LinkedIn Profile for maximum exposure and top search ranking using targeted keywords The secrets to leveraging LinkedIn Recommendations Tips on integrating LinkedIn into the rest of your Social Media Strategy The "How to ...
Tags: Marketing4mainst How-to Marketing Internet Marketing Digital Marketing Business Main Street Marketing pete sabine cheryl liquori CCAR Type 1 Diabetes Research - OmniBio CEO Dr. James Crapo
Uploaded by: OmniBioPDescription:
OmniBio CEO Dr. James Crapo talks about the important research taking place with Alpha-1 Antitrypsin (AAT). This safe and powerful molecule is being used in trials for type 1 diabetes and Graph vs. Host disease (GVH). OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com
Tags: graft host disease bone marrow transplant clinical trials alpha type 1 mellitus research cure alpha-1 antitrypsin aat jdrf juvenile children's diabetes foundation pharmaceutical industry stock investment opportunity angel investor equity development public company business finance funding portfolio venture capital startup small cap market financing healthcare health care medical westmountain West Mountain Asset Management Omni Bio James Crapo Charles Dinarello University of Colorado

Providers:
3087
Cash Reward:
$525,161






